Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907852 | 1.00 | CES2 (0.42) | CES2CES1KMT2AMEN1ALDH1A1 | |
| SCHEMBL29659379 | 0.88 | SMN1; SMN2 (0.39) | CES2CES1KMT2AMEN1ALDH1A1 | |
| SCHEMBL21379847 | 0.85 | CES2 (0.56) | CES2CES1KMT2AMEN1ALDH1A1 | |
| SCHEMBL29907838 | 0.79 | CES2 (0.42) | CES2CES1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL23270675 | 0.79 | CES2 (0.42) | CES2CES1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL23301730 | 0.78 | CES2 (0.45) | CES2CES1KMT2AMEN1ALDH1A1 | |
| SCHEMBL29723949 | 0.78 | CES2 (0.45) | CES2CES1KMT2AMEN1ALDH1A1 | |
| SCHEMBL31455640 | 0.75 | PTGS1 (0.38) | CES2CES1KMT2AMEN1ALDH1A1 | |
| SCHEMBL2875036 | 0.73 | NFE2L2 (0.37) | CES2CES1ALDH1A1KDM4EERN1 | |
| SCHEMBL29931004 | 0.73 | CA12 (0.47) | CES2CES1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2025-02-06 | — | — | US | disclosed |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | INCYTE CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117500503-A | Combination therapy comprising an A2A/A2B inhibitor, a PD-1/PD-L1 inhibitor and an anti-CD 73 antibody | 因赛特公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4271384-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | Incyte Corporation (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-115551595-A | Combination therapy of a CD73 inhibitor and an A2A/A2B adenosine receptor inhibitor | 因赛特公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-4085060-A1 | COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11168089-B2 | Fused pyrimidine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168089-B2 | Fused pyrimidine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210230294-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-20210230294-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2021-07-29 | — | — | US | disclosed |
| WO-2021138512-A1 | COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138512-A1 | COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138498-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20210205311-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2021-07-08 | — | — | US | disclosed |
| US-20210205311-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2021-07-08 | — | — | US | disclosed |
| EP-3810610-A1 | FUSED PYRIMIDINE DERIVATIVES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | CES2 3417/4885CES1 2429/4885KMT2A 2399/4885 |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | ADORA2A, ADORA2B, NT5E | CES2 1440/4885CES1 1470/4885KMT2A 2021/4885 |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | CES2 1440/4885CES1 1470/4885KMT2A 2021/4885 |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | CES2 4314/4885CES1 3343/4885KMT2A 1092/4885 |
| US-20210230294-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | CES2 1440/4885CES1 1470/4885KMT2A 2021/4885 |
| US-11168089-B2 | Fused pyrimidine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | CES2 3417/4885CES1 2429/4885KMT2A 2399/4885 |
| US-20210205311-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | CES2 4314/4885CES1 3343/4885KMT2A 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.